We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported adjusted earnings per share (EPS) of 65 cents in the second quarter of 2017, missing the Zacks Consensus Estimate by a penny. Earnings were also lower than 76 cents recorded in the year-ago quarter.
Quarter Details
Net sales decreased to $992.7 million from $1,022.0 million in the year-ago period. Also, the figure lagged the Zacks Consensus Estimate of $1,004.0 million. Sales of the combined businesses decreased 2.2% at constant currency (cc) exchange rates. In the reported quarter, sales were affected by inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
In the quarter, U.S. sales fell 9.7% to $331.6 million, while net sales in Europe increased 2.5% to $402.2 million. Sales of the combined business declined 9.6% at cc in the U.S., while European sales rose 5.7%.
Net sales in Rest of World decreased 1.3% to $258.9 million. Sales in Rest of World of the combined business rose 1.3% at cc.
Segment Details
The business is organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Dental & Healthcare Consumables comprises preventive, restorative, instruments, endodontic and laboratory dental products as well as consumable medical device products. Sales increased 1.9% to $554.1 million. At cc, sales of the segment rose 3.0% year over year in the quarter.
Technologies consist of dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products. Net sales decreased 8.3% to $438.6 million. At cc, sales of the combined business fell 5.6% in the reported quarter.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
Total cash and cash equivalents of the company decreased to $268.4 million as of Jun 30 from $383.9 million as of Dec 31, 2016. Cash generated from operations in the first half of 2017 was $208.7 million compared with $188.1 million in the year-ago period. As of Jun 30, the company’s long-term debt was $1.59 billion versus $1.51 billion at year-end 2016.
Guidance
For 2017, the company anticipates adjusted EPS in the range of $2.65 to $2.75.
Zacks Rank & Key Picks
Currently, DENTSPLY carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Fresenius Medical Care Corporation (FMS - Free Report) and Dextera Surgical Inc. .
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 5.9% over the last three months.
Fresenius Medical yielded a strong return of 9.3% year to date. The stock has a long-term expected earnings growth rate of 10.1%.
Dextera has a projected sales growth of 54.8% for the current year. The stock promises a long-term expected earnings growth rate of 25%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported adjusted earnings per share (EPS) of 65 cents in the second quarter of 2017, missing the Zacks Consensus Estimate by a penny. Earnings were also lower than 76 cents recorded in the year-ago quarter.
Quarter Details
Net sales decreased to $992.7 million from $1,022.0 million in the year-ago period. Also, the figure lagged the Zacks Consensus Estimate of $1,004.0 million. Sales of the combined businesses decreased 2.2% at constant currency (cc) exchange rates. In the reported quarter, sales were affected by inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
In the quarter, U.S. sales fell 9.7% to $331.6 million, while net sales in Europe increased 2.5% to $402.2 million. Sales of the combined business declined 9.6% at cc in the U.S., while European sales rose 5.7%.
Net sales in Rest of World decreased 1.3% to $258.9 million. Sales in Rest of World of the combined business rose 1.3% at cc.
Segment Details
The business is organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Dental & Healthcare Consumables comprises preventive, restorative, instruments, endodontic and laboratory dental products as well as consumable medical device products. Sales increased 1.9% to $554.1 million. At cc, sales of the segment rose 3.0% year over year in the quarter.
Technologies consist of dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products. Net sales decreased 8.3% to $438.6 million. At cc, sales of the combined business fell 5.6% in the reported quarter.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Financial Update
Total cash and cash equivalents of the company decreased to $268.4 million as of Jun 30 from $383.9 million as of Dec 31, 2016. Cash generated from operations in the first half of 2017 was $208.7 million compared with $188.1 million in the year-ago period. As of Jun 30, the company’s long-term debt was $1.59 billion versus $1.51 billion at year-end 2016.
Guidance
For 2017, the company anticipates adjusted EPS in the range of $2.65 to $2.75.
Zacks Rank & Key Picks
Currently, DENTSPLY carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Fresenius Medical Care Corporation (FMS - Free Report) and Dextera Surgical Inc. .
Notably, Edwards Lifesciences and Fresenius Medical sport a Zacks Rank #1 (Strong Buy), while Dextera has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 5.9% over the last three months.
Fresenius Medical yielded a strong return of 9.3% year to date. The stock has a long-term expected earnings growth rate of 10.1%.
Dextera has a projected sales growth of 54.8% for the current year. The stock promises a long-term expected earnings growth rate of 25%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>